Literature DB >> 26383643

Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels.

Jong Chan Im1, Jae Pil Shin1, In Taek Kim1, Dong Ho Park2.   

Abstract

PURPOSE: To measure unaffected retinal vessel diameter in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) after intravitreal injection with bevacizumab (IVB).
METHODS: Patients with BRVO-induced ME who responded to IVB were assessed at baseline and 1, 3, and 6 months. In both eyes, the diameters of the largest arteriole and venule in all quadrants (except occlusion quadrant) were measured by using a computer-assisted method. The same vessels chosen at baseline were measured at each follow-up examination.
RESULTS: Forty-two eyes were participated. At baseline, venular diameters of unaffected quadrants in eyes with BRVO were larger than the venules in the corresponding quadrant of the fellow eyes (p < 0.05, respectively). The venular diameters in all quadrants of the affected eyes decreased significantly relative to baseline after IVB (p < 0.05 respectively). Twenty-two eyes (52.4 %) developed recurrent ME. On recurrence at 3 (n = 15, 35.7 %) or 6 months (n = 7, 16.7 %), the unaffected venular diameters increased significantly (p < 0.05 respectively). These diameters again decreased significantly after a second IVB (p < 0.05 respectively).
CONCLUSION: Unaffected retinal venular diameters associate with the course of BRVO with ME. This may help elucidate the pathological mechanism underlying BRVO.

Entities:  

Keywords:  Branch retinal vein occlusion; Macular edema; Retinal vessel diameter

Mesh:

Substances:

Year:  2015        PMID: 26383643     DOI: 10.1007/s00417-015-3175-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.

Authors:  Shuzo Kaneda; Dai Miyazaki; Shin-ichi Sasaki; Keiko Yakura; Yuki Terasaka; Ken-ichiro Miyake; Yoshifumi Ikeda; Taisaku Funakoshi; Takashi Baba; Atsushi Yamasaki; Yoshitsugu Inoue
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-06       Impact factor: 4.799

2.  Prevalence and risk factors of retinal vein occlusion in an Asian population.

Authors:  L L Lim; N Cheung; J J Wang; F M A Islam; P Mitchell; S M Saw; T Aung; T Y Wong
Journal:  Br J Ophthalmol       Date:  2008-08-06       Impact factor: 4.638

Review 3.  Prevalent misconceptions about acute retinal vascular occlusive disorders.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2005-07       Impact factor: 21.198

Review 4.  Optic nerve oxygenation.

Authors:  Einar Stefánsson; Daniella Bach Pedersen; Peter Koch Jensen; Morten la Cour; Jens Folke Kiilgaard; Kurt Bang; Thor Eysteinsson
Journal:  Prog Retin Eye Res       Date:  2004-12-20       Impact factor: 21.198

5.  Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.

Authors:  R G Tilton; K C Chang; W S LeJeune; C C Stephan; T A Brock; J R Williamson
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

6.  Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.

Authors: 
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-07       Impact factor: 4.799

Review 7.  Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature.

Authors:  Adil Jaulim; Badia Ahmed; Tina Khanam; Irini P Chatziralli
Journal:  Retina       Date:  2013-05       Impact factor: 4.256

Review 8.  The treatment of branch retinal vein occlusion with bevacizumab.

Authors:  Federico Badalà
Journal:  Curr Opin Ophthalmol       Date:  2008-05       Impact factor: 3.761

9.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

Authors:  Tim U Krohne; Nicole Eter; Frank G Holz; Carsten H Meyer
Journal:  Am J Ophthalmol       Date:  2008-07-17       Impact factor: 5.258

10.  Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins.

Authors:  Stephan A Fraenkl; Maneli Mozaffarieh; Josef Flammer
Journal:  EPMA J       Date:  2010-06-18       Impact factor: 6.543

View more
  4 in total

1.  Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels.

Authors:  Jong Chan Im; Jae Pil Shin; In Taek Kim; Dong Ho Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-20       Impact factor: 3.117

2.  Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels.

Authors:  Umit Yolcu; Abdullah Ilhan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-19       Impact factor: 3.117

3.  Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion.

Authors:  Tomoharu Nishimura; Shigeki Machida; Atsushi Tada; Eiki Oshida; Tetsuya Muto
Journal:  Doc Ophthalmol       Date:  2019-04-12       Impact factor: 2.379

4.  Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion.

Authors:  Wenyi Tang; Wei Liu; Jingli Guo; Lili Zhang; Gezhi Xu; Keyan Wang; Qing Chang
Journal:  Eye Vis (Lond)       Date:  2022-07-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.